- Astellas Pharma‘s net sales for the third quarter reached 517.41 billion yen, a 23% increase year-over-year, surpassing the estimated 448.77 billion yen.
- The sales of Betanis/Myrabetriq/Betmiga were 47.0 billion yen, matching last year’s performance and exceeding the estimate of 29.49 billion yen.
- Prograf sales were slightly down by 6.5% year-over-year at 51.7 billion yen, above the estimated 49.56 billion yen.
- Xtandi sales showed significant growth at 251.4 billion yen, a 26% increase year-over-year.
- The company reported an operating loss of 116.19 billion yen, compared to a profit of 23.10 billion yen the previous year and an expected profit of 74.22 billion yen.
- A net loss of 97.66 billion yen was recorded, contrasting with a profit of 18.65 billion yen the year before and below the estimated profit of 24.67 billion yen.
- Research and development expenses rose by 6.3% year-over-year to 79.1 billion yen, which was below the estimated 86.39 billion yen.
- The company maintains its yearly forecast for operating income at 11.00 billion yen and net income at 14.00 billion yen, despite an estimated net income of 62.58 billion yen.
- Astellas still forecasts net sales of 1.90 trillion yen, higher than the estimated 1.83 trillion yen.
- The expected dividend remains at 74.00 yen, marginally below the estimated 74.06 yen.
- Analyst recommendations include 9 buys, 7 holds, and 1 sell.
“`
Astellas Pharma on Smartkarma
Analyst coverage of Astellas Pharma on Smartkarma reveals positive sentiments towards the company’s recent performance and future outlook. Tina Banerjee‘s research reports highlight significant developments for Astellas Pharma (4503 JP). In the report “Astellas Pharma (4503 JP): Xtandi & Forex Lead To Guidance Revision, Impairment Losses One Off Burnt,” the company raised its FY25 revenue guidance to ¥1900B, indicating strong performance driven by Xtandi and favorable forex movement. However, there is a recorded impairment charge of ¥176B for intangible assets impacting reported profits. Additionally, in the report “Astellas Pharma (4503 JP): US Momentum Drives 1HFY25 Result; Guidance Revised Upward,” Astellas reported a 22% revenue growth in H1FY25, with Xtandi and Padcev driving future growth prospects. Guidance for FY25 has been revised upward to ¥1800B, with expectations of rising core operating profit and net profit despite margin pressures.
A look at Astellas Pharma Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Astellas Pharma is positioned with a solid Dividend score of 5, indicating strong potential for dividend payouts to investors. This highlights the company’s commitment to rewarding shareholders with consistent and attractive dividends over the long term. Furthermore, Astellas Pharma scores moderately in terms of Value, Growth, Resilience, and Momentum, showcasing a balanced overall outlook.
Astellas Pharma Inc., a leading pharmaceutical company, focuses on various therapeutic fields such as Urology, Immunology, Oncology, Neuroscience, and Metabolic Diseases. With a robust workforce of over 17,000 employees globally, the company conducts extensive research, development, manufacturing, and promotion of prescription drugs worldwide through its subsidiaries in key regions like the US, Europe, and Asia. The combination of its strong dividend performance and diverse field presence positions Astellas Pharma as a noteworthy player in the pharmaceutical industry for long-term growth and stability.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
